Status:
COMPLETED
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
This international study is a prospective noninterventional observational cohort study of patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditio...
Eligibility Criteria
Inclusion
- Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism, and who consent to participate in the study.
Exclusion
Key Trial Info
Start Date :
January 14 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2016
Estimated Enrollment :
2101 Patients enrolled
Trial Details
Trial ID
NCT01800006
Start Date
January 14 2013
End Date
June 20 2016
Last Update
June 21 2017
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Argentina
2
Many Locations, Azerbaijan
3
Many Locations, Bahrain
4
Many Locations, Chile